Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02531919 · ClinicalTrials.gov registry record · Phase 1
Extended Use of Sodium Bicarbonate in Patients With Cancer
A Phase 1 study of Malignant Neoplasm, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02531919 is a Phase 1 study of Malignant Neoplasm that has completed, run by University of Arizona. The registered enrollment target is 15 participants, below the 513-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02531919, a Phase 1 study of Malignant Neoplasm, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot phase I trial studies the safety of long-term use of sodium bicarbonate in patients with cancer. Sodium bicarbonate may neutralize tumor acidity and as a result may inhibit the spread of the tumor to other parts of the body (metastases) and improve survival.
Conditions Studied
Interventions
- DRUG Sodium Bicarbonate
Study Locations (1)
Arizona
- University of Arizona Medical Center-University Campus - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02531919
The ClinicalTrials.gov registry entry for NCT02531919 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 513-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (97% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Sodium Bicarbonate is the first listed.
NCT02531919 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT02531919 about?
NCT02531919 is a clinical study titled "Extended Use of Sodium Bicarbonate in Patients With Cancer". This pilot phase I trial studies the safety of long-term use of sodium bicarbonate in patients with cancer. Sodium bicarbonate may neutralize tumor acidity and as a result may inhibit the spread of the tumor to other parts of the body (metastases) and improve survival.
What is the current status of trial NCT02531919?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-08. Estimated completion is 2015-05.
What conditions does trial NCT02531919 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT02531919?
The interventions under investigation include: Sodium Bicarbonate (DRUG).
Who is sponsoring clinical trial NCT02531919?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02531919 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
-
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
RECRUITING · Phase 1
-
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
RECRUITING · Phase 1
-
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.